Stay updated on IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial

Sign up to get notified when there's something new on the IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:53:23.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or revision in the dosing regimen of the immunotherapeutic agent indoximod in combination with gemcitabine and nab-paclitaxel for patients with metastatic adenocarcinoma of the pancreas.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:19.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying that patients must have confirmed metastatic adenocarcinoma of the pancreas and meet other health and treatment history requirements. Previously, no information was provided under Participation Criteria for Collaborators and Investigators.
    Difference
    23%
    Check dated 2024-05-22T20:53:28.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:29:04.000Z thumbnail image

Stay in the know with updates to IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial page.